TrialThe Journal of infectious diseases2025

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine.

Spyros Chalkias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.